Document:

CONFIDENTIAL TREATMENT REQUESTED
(The redacted  material,  indicated by [*], has been  separately  filed with the
Commission)

                          AMENDMENT TO SUPPLY AGREEMENT

This Amendment to the Supply  Agreement  ("Amendment")  is entered into this 5th
day of  November,  1999 by and between  Phar-Mor,  Inc.  LLC and its  affiliates
("Phar-Mor")  and  McKesson  Drug  Company,  a division of McKesson  HBOC,  Inc.
("McKesson"), formerly McKesson Corporation.

                                  INTRODUCTION

Pursuant to the terms of the Supply  Agreement  dated June 19, 1997 (the "Supply
Agreement"),  McKesson and Phar-Mor, Inc. entered into an agreement to establish
a prime vendor  relationship  whereby  McKesson  serves as the supply  source of
pharmaceutical and OTC products for Phar-Mor and its retail pharmacies.

Phar-Mor,  Inc.  has recently  purchased  all of the assets of  Pharmhouse  (the
"Transaction").  In view of the Transaction, Phar-Mor and McKesson now desire to
amend the Supply Agreement as set forth below.

                                    AGREEMENT

For good and  valuable  consideration,  McKesson  and  Phar-Mor  hereby agree as
follows:

1.       McKesson  hereby  acknowledges  the  assignment  of all of the tangible
         assets,  rights and obligations of Phar-Mor,  Inc. including the Supply
         Agreement,  to its  affiliate,  Phar-Mor,  Inc.  LLC on June 27,  1997.
         Phar-Mor,  Inc. LLC remains a wholly-owned affiliate of Phar-Mor,  Inc.
         and its wholly-owned subsidiary,  Phar-Mor of Wisconsin,  Inc. Inasmuch
         as the retail  pharmacies  subject to this  Agreement  are  operated by
         wholly-owned subsidiaries and affiliates of Phar-Mor, Inc., the parties
         agree that the appropriate parties to the Supply Agreement, as amended,
         should be Phar-Mor,  Inc. LLC and its  affiliates,  and McKesson hereby
         agrees  to  such  assignment  of  the  Supply  Agreement.  Accordingly,
         hereinafter  all references to Phar-Mor  shall refer to Phar-Mor,  Inc.
         LLC and its affiliates.

2.       Section 8 of the Supply Agreement shall be amended to reflect an annual
         purchase  commitment of [ * ] (net of returns,  allowances and rebates)
         in volume of D.S.D. Merchandise by Phar-Mor.

3.       The term of the Supply Agreement as defined in Section 11 thereof shall
         be modified by this  Amendment  to extend for an  additional  four-year
         period through  November 15, 2005. For purposes  hereof,  each Contract
         Year  during the term of the Supply  Agreement  shall be defined as the
         twelve (12) month period commencing on November 15.

4.       Section 9 of the  Agreement  shall be modified by adding the  following
         payment terms:

         McKesson agrees to provide Phar-Mor with [ * ] [(*)] day payment terms.
         All invoices for each week (Sunday  through  Saturday)  will be due and
         payable via wire  transfer on the [ * ] day  following  the end of each
         week.  If any of the due dates  herein  fall on a weekend  or  holiday,
         payment will be due the next business day. All late charges as noted in
         Section 9 of the Supply  Agreement will apply to unpaid  balances.  The
         availability  of such payment terms and conditions as specified in this
         Section 4 of the Amendment is based on and  contingent  upon payment by
         Phar-Mor via wire transfer.  Until such time as Phar-Mor begins payment
         by wire transfer,  the existing  payment terms in the Supply  Agreement
         shall apply.

5.       The first  paragraph of Section 7 Purchase  Price:  Definition  of Cost
         will be deleted in its entirety and replaced with the following:

         The purchase  price of the  Merchandise  delivered to Phar-Mor shall be
         the Cost of the Merchandise less the reductions or plus the markup,  as
         applicable,  set  forth  in the  cost of goods  schedule  set  forth in
         Section 19 below.  Except in the case of  contract  items as  discussed
         below,  "Cost"  means the  manufacturer's  published  acquisition  cost
         (exclusive  of cash  discounts)  on the date of  McKesson's  invoice to
         Phar-Mor, adjusted for selected bonus goods, manufacturers' off-invoice
         allowances  and  manufacturers'  deal  prices to be made  available  to
         Phar-Mor  in  accordance  with  McKesson's  established  policies.  For
         purchases of  Merchandise  with  respect to which  Customer has entered
         into a vendor contract with a manufacturer ("Contract Products") loaded
         with McKesson,  "Cost" shall mean the "bid price" of the product as set
         forth in the vendor contract.

6.       The Developmental Funds subsection in Section 8 of the Supply Agreement
             -------------------
         will be deleted in its entirety and replaced with the following:

         In  consideration  for the  initial  two  years of the  four-year  term
         extension as specified in Section 3 of this Amendment,  McKesson agrees
         to pay to Phar-Mor the following amounts:

         (i)      the sum of [ * ] ("Developmental  Funds") within ten (10) days
                  of the  Select  Implementation  Date as  herein  defined.  For
                  purposes hereof, the Select Implementation Date shall mean the
                  date on which all Phar-Mor and Pharmhouse  locations are fully
                  participating     in    the    McKesson     Select    Generics
                  auto-substitution program; and

         (ii)     the sum of [ * ] ("Continuing  Commitment  Funds") on November
                  15, 2001.

         In the event that the Supply  Agreement is  terminated  by either party
         for any reason during the term hereof (other than a material  breach of
         the Supply  Agreement by McKesson that is not cured by McKesson  within
         sixty (60) days of Phar-Mor's  notice  thereof,  upon  termination  for
         which  Phar-Mor  shall not be  required to repay such  amounts  already
         paid),  Phar-Mor  shall  immediately  reimburse  to  McKesson  the then
         applicable  portion  of the  above-specified  Developmental  Funds  and
         Continuing  Commitment  Funds as determined  by the following  pro-rata
         reimbursement formulas:

         Reimbursement Formula for Previously Paid Developmental Funds
         -------------------------------------------------------------

        |-----                                                        -----|
        |                                                                  |
        |                      Number of months remaining in the Supply    |
        |                      Agreement between the date of termination   |
        |  [   *   ] times     and November 15, 2003                       |
        |                      ----------------------------------------    |
        |                                      60                          |
        |                                                                  |
        |                                                                  |
        |-----                                                        -----|

         Reimbursement Formula for Previously Paid Continuing Commitment Funds

         |-----                                                       -----|
         |                                                                 |
         |                      Number of months remaining in the Supply   |
         |                      Agreement between the date of termination  |
         |  [   *   ] times     and November 15, 2003                      |
         |                      -----------------------------------------  |
         |                                          24                     |
         |                                                                 |
         |-----                                                       -----|

7.       Section 19 Cost of Goods, will be deleted in its entirety and  replaced
                    -------------
         with the following:

         The  Retail  Cost of Goods  set  forth in this  Section  19 is based on
         Phar-Mor  achieving  the  following  purchase  volumes in Direct  Store
         Delivery ("D.S.D.") prescription drug and OTC product purchases (net of
         returns,  allowances and rebates) from McKesson  throughout the term of
         this Agreement:

          (i)   $[ * ] in total  chainwide  annual  purchases;  and
          (ii)  minimum  chainwide average of $[ * ] per store per month.

Retail Direct Store Delivery
----------------------------

         RX                Cost Minus                [   *   ]%
         OTC               Cost Minus                [   *   ]%

Pharmhouse Transition OTC Cost of Goods

Subject to the terms and conditions herein, all former Pharmhouse locations will
be billed at Cost  Minus [ * ]% on OTC  products  as per this  Section 19 of the
Supply Agreement.  This cost will remain effective as long as such OTC purchases
remain  consistent  with  Phar-Mor's   current  practices  and  do  not  include
Non-Ethical  OTC and General  Sundries  which are to be provided to the Phar-Mor
and Pharmhouse stores by the Phar-Mor warehouse.

Phar-Mor  stores will be invoiced at Cost Plus [ * ]%. Provided that Phar-Mor is
maintaining a minimum  chainwide  monthly  average net volume of [ * ] in D.S.D.
purchases  per  store,  McKesson  will  provide a monthly  rebate to  Phar-Mor's
corporate  offices in the amount of [ * ]% on  discountable Rx purchases and [ *
]% of discountable OTC purchases (net of returns and  allowances).  In the event
that Phar-Mor's  chainwide monthly average net purchase volume per store is less
than $[ * ], the monthly rebate will be the difference between the invoice price
and the  applicable  cost of  goods.  Items  that are  billed  at a net price as
outlined in Section 7 of the Supply  Agreement will be excluded from the monthly
rebate.

In the event that Phar-Mor fails to maintain a minimum  chainwide average volume
of $[ * ] in net D.S.D.  prescription  drug and OTC product  purchases per store
per  month  from  McKesson  during  any  three  (3)  consecutive  months of this
Agreement,  all retail cost of goods pricing hereunder shall be increased to the
then applicable  pricing based on the following  schedule until such time as the
minimum  chainwide D.S.D.  prescription drug and OTC product net purchase volume
requirement of $[ * ] is met for three (3) consecutive months, at which time the
retail cost of goods  pricing  shall return to Cost minus [ * ]% for Rx and Cost
minus [ * ]% for OTC products.

             Chainwide Monthly
             Average Per Store                         Rx             OTC
             (net of returns,                          --             ---
             allowances and rebates)
             -----------------------
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]
             $[   *   ]                             [   *   ]       [   *   ]

         It is further  understood  and agreed by both  parties that if Phar-Mor
         fails to maintain a minimum  chainwide  average  volume of [ * ] in net
         D.S.D.  prescription drug and OTC product purchases per store per month
         from  McKesson  during  any  rolling  three  (3)  month  period of this
         Agreement, such failure shall constitute a default of this Agreement by
         Phar-Mor.

8.       The Annual  Volume  Incentive  subsection as set forth in Section 19 of
             -------------------------
         the Supply Agreement will be deleted in its entirety;  provided however
         that within thirty (30) days of the execution of this Amendment by both
         parties, McKesson will pay to Phar-Mor a volume incentive payment based
         on  Phar-Mor's  purchase  volume  of D.S.D.  prescription  drug and OTC
         products  (net of  returns,  allowances  and  rebates)  for the  period
         between  November  1, 1998 and July 1, 1999 in the  amount of [ * ]% of
         net total purchases during such period.

9.       Section 20 Generic  Pharmaceuticals will be deleted in its entirety and
                    ------------------------
         replaced with the following:

         Phar-Mor agrees to participate in McKesson's  Select  Generics  Program
         through its  auto-substitution  feature and to thereby  designate  this
         program  as the  primary  source  of  generic  pharmaceuticals  for all
         Phar-Mor and Pharmhouse stores. The Select  Implementation Date for all
         such   stores  will  occur  on  or   before-January   31,   2000.   All
         Phar-Mor/Pharmhouse  pharmacies  will be  billed  for  McKesson  Select
         Generics at discounted  bid prices,  which are subject to change due to
         market  conditions.  In  addition,  a  quarterly  rebate  will  be paid
         Phar-Mor  following the Select  Implementation  Date in accordance with
         the following schedule:

       Chainwide Quarterly McKesson Select Generics    Rebate Percent
       Purchases (net                                  on Net McKesson
       of returns allowances and rebates)              Select Generics Purchases
       ----------------------------------              -------------------------
       Less than [   *   ]                                            [   *   ]%
       and above                                                      [   *   ]%
                                                                      [   *   ]%

All  Phar-Mor/Pharmhouse  locations must be fully  participating in the McKesson
Select  Generic  auto-substitution  program in order for Phar-Mor to qualify for
any quarterly rebate hereunder. Notwithstanding anything herein to the contrary,
the quarterly McKesson Select Generics minimum purchase volume of [ * ] required
to obtain the  above-specified  rebate will be waived for the period between the
Select  Implementation  Date as  referenced  above and March 31, 2000,  and with
respect to such period the following rebate payment percentages shall apply:

|X|      [ * ]% if net McKesson Select Generics  purchase volume is less than
         $[ * ].

|X|      [ * ]% if net McKesson  Select  Generics  purchase  volume is $[ * ] or
         greater.

Rebate payments pursuant to this Section 20 will be made to Phar-Mor's corporate
offices within 30 days of the end of each quarter.

a.       Market Competitiveness
         ----------------------

         McKesson  shall  provide a Select  Generics  Benchmark  each quarter to
         ensure  Phar-Mor of the market  competitiveness  of the McKesson Select
         Generics Program.

b.       Service Level
         -------------

         McKesson will ensure a [ * ] service level,  as defined in Section 13.A
         of the Supply  Agreement for products  purchased on the McKesson Select
         Generics  Program.  If McKesson fails to meet this [ * ]% service level
         for Select Generics Program purchases for two (2) consecutive quarters,
         then  McKesson  will pay Phar-Mor an amount equal to [ * ] basis points
         ([ * ]%) of Phar-Mor's total Select Generics purchases (net of returns,
         allowances  and rebates)  during the subject period within fifteen (15)
         days following Phar-Mor's demand for same.

c.       New-to-Market Generics Features
         -------------------------------

         |X|      Stocking allowances / slotting fees on New-to-Market  products
                  will be passed to  Phar-Mor  when made  available  to McKesson
                  from the manufacturer.

         |X|      Free  goods  and/or  automatic   shipment  for   New-to-Market
                  products will be provided to Phar-Mor  when made  available to
                  McKesson from the manufacturer.

10.  Section 21.  Repack  Pharmaceuticals  will be deleted in its  entirety  and
                  -----------------------
replaced by the following:

         Repack Pharmaceuticals
         ----------------------

         A comprehensive program will be made available to Phar-Mor for repacked
         pharmaceuticals.  Stores shall be net-billed with an additional  volume
         rebate to be paid to Phar-Mor headquarters, each quarter.

          Quarterly RxPak Volume                              Rebate % on
          (net of returns, allowances & rebates)              Net RxPak Volume
          --------------------------------------              ----------------
          Less than $ [   *   ]                                   [   *   ]%
          $ [   *   ] - $[   *   ] million                        [   *   ]%
          $ [   *   ] - $[   *   ] million                        [   *   ]%
          $ [   *   ] - $[   *   ] million                        [   *   ]%
          $ [   *   ] - $[   *   ] million                        [   *   ]%
          $ [   *   ] million and above                           [   *   ]%

11.      The  reimbursement  formula  specified  at the end of Section 15 of the
         Supply Agreement shall be deleted in its entirety and replaced with the
         following:

     |-----                      -----|       |-----                     -----|
     |   Total amount of On-Site      |       | Number of months remaining    |
     |   Support Monies paid by       |       | in the then current Contract  |
     |  McKesson to Phar-Mor for      | times | year upon date of termination |
     |  the then current Contract Year|       | ----------------------------- |
     |                                |       |              12               |
     |-----                      -----|       |-----                     -----|

12.      Provided  that  all  of  Phar-Mor's  material  contractual  commitments
         required  under  this  Supply  Agreement  have  been  met for the  then
         concluding  Contract  Year as of each of the  designated  dates  below,
         McKesson  will  provide to  Phar-Mor  an annual  compliance  payment in
         accordance with the following schedule:

         $[   *   ] payable November 15, 2000
         $[   *   ] payable November 15, 2001
         $[   *   ] payable November 15, 2002
         $[   *   ] payable November 15, 2003
         $[   *   ] payable November 15, 2004
         $[   *   ] payable November 15, 2005

         In  the  event  that   Phar-Mor   fails  to  qualify  for  any  of  the
         above-specified payments due to nonperformance of its material contract
         commitments in any given Contract Year, that particular payment will be
         deemed  forfeited  and McKesson will have no liability or obligation to
         subsequently make such payment available to Phar-Mor.

13.      The Supply Agreement  between  Pharmhouse  Corporation and the McKesson
         U.S.  Healthcare division of McKesson  Corporation,  dated May 1, 1998,
         shall be deemed  terminated  upon the execution of this  Amendment.  No
         damages  or other  amounts,  other  than trade  payables  and  McKesson
         PaySystem  receivables,   shall  be  owed  to  McKesson  by  Pharmhouse
         Corporation  or by Phar-Mor,  Inc. or its  subsidiaries  or  affiliates
         based on that Supply Agreement.

14. All terms and conditions of this Amendment  shall be deemed  effective as of
July 1, 1999.

15. Except as modified above, the Supply Agreement remains unchanged and in full
force and effect.

IN  WITNESS  WHEREOF  the  parties  have  caused  this  Amendment  to the Supply
Agreement to be duly executed as, of the day and year specified above.

PHAR-MOR, INC. LLC AND ITS AFFILIATES,         McKESSON DRUG COMPANY,
BY PHAR-MOR, INC.LLC                           a division of McKesson HBOC, Inc.

By:   /s/ David Schwartz                        By:  /s/ Mark J. Majeske
      ------------------                             -------------------
Name:  David Schwartz                           Name:  Mark T. Majeske
       -----------------                               -----------------
Title: President & COO                          Title: Group President, Retail
       ---------------                                 and Customer Operations
                                                       -----------------------

Date:  November 5, 1999                         Date:  November 10, 1999
       ----------------                                -----------------

dc-186344<PAGE>

                      FRONTLINE COMMUNICATIONS CORPORATION

                                 ---------------

                           CERTIFICATE OF DESIGNATION
                                       OF
                         SERIES B CUMULATIVE CONVERTIBLE
                                 PREFERRED STOCK

                                 ---------------

                (Pursuant to Section 151 of the Delaware General
                                Corporation Law)

         The undersigned, the authorized officer of Frontline Communications
Corporation, a Delaware corporation (the "Corporation"), in accordance with the
provisions of Section 103 of the Delaware General Corporation Law (the "DGCL")
does hereby certify that, in accordance with Section 141 of the DGCL, the
following resolution was duly adopted by the Board of Directors of the
Corporation on ___________, 2000:

         RESOLVED, that a series of Preferred Stock of the Corporation is hereby
created and the designation, number of shares, powers, preferences, rights,
qualifications, limitations and restrictions thereof (in addition to any
provisions set forth in the Certificate of Incorporation of the Corporation
which are applicable to the preferred stock of all classes and series) are as
follows:

                       SERIES B CUMULATIVE CONVERTIBLE
                                 PREFERRED STOCK

         Section 1. Designation and Amount; Stated Capital. The shares of such
series shall be designated as "Series B Cumulative Convertible Preferred Stock"
(the "Series B Convertible Preferred Stock"), the par value thereof shall be
$.01 per share and the number of shares constituting the Series B Convertible
Preferred Stock shall be 1,250,000. The amount to be represented in stated
capital at all times for each share of Series B Convertible Preferred Stock
shall be $.01.

         Section 2. Rank. With respect to dividend rights and rights on
liquidation,

<PAGE>

winding-up and dissolution, the Series B Convertible Preferred Stock will rank:
(i) senior to: (A) the common stock, par value $.01 per share (the "Common
Stock"); (B) all other classes of common stock and (C) each other class or
series of preferred stock of the Corporation now or hereafter established by the
Board of Directors (the "Board of Directors" or the "Board") of the Corporation,
the terms of which do not expressly provide that it ranks senior to, or on a
parity with, the Series B Convertible Preferred Stock as to dividend and
redemption rights and rights on liquidation, winding-up and dissolution of the
Corporation (collectively referred to as "Junior Stock"); (ii) on a parity with
each other class or series of preferred stock of the Corporation established
hereafter by the Board of Directors, the terms of which expressly provide that
such class or series will rank on a parity with the Series B Convertible
Preferred Stock as to dividend and redemption rights and rights on liquidation,
winding-up and dissolution (collectively referred to as "Parity Stock"); and
(iii) junior to each class or series of preferred stock of the Corporation
established hereafter by the Board, the terms of which class or series expressly
provide that such class or series will rank senior to the Series B Convertible
Preferred Stock as to dividend and redemption rights or rights on liquidation,
winding-up and dissolution of the Corporation (collectively referred to as
"Senior Stock").

         Section 3. Dividends and Distributions.

         (a) The holders of shares of Series B Convertible Preferred Stock shall
be entitled to receive, when, as and if declared by the Board of Directors out
of funds legally available for such purpose, cumulative dividends at the rate of
$_____ per share of the Series B Convertible Preferred Stock per annum, and no
more. The dividend on each share of Series B Convertible Preferred Stock shall
accrue from the date of its original issuance. The dividend shall be payable on
the last business day of June and December of each year, commencing on June 30,
2000, to the holders of record as they appear on the stock books of the
Corporation on such record dates, not more than 60 nor less than 10 days
preceding the payment dates for such dividends, as shall be fixed by the Board.
The amount of dividends payable per share of Series B Convertible Preferred
Stock for each semi-annual dividend period shall be computed by dividing the
annual dividend amount by two. The amount of dividends payable for the initial
dividend period and any period shorter than a full semi-annual dividend period
shall be computed on the basis of a 365-day year and the actual days elapsed.

         (b) Any dividends on the Series B Convertible Preferred Stock payable
pursuant to this Section 3 may be paid, at the Corporation's option, either in
cash or by the issuance of shares of Common Stock having an average daily
Closing Price (as hereinafter defined), on the five consecutive trading days
immediately preceding the day prior to the record date for the determination of
stockholders entitled to receive such dividend, equal to the amount of such
dividends; provided, however, that cash will be paid in lieu of the issuance of
fractional shares of

<PAGE>

Common Stock; and provided, further, that accrued and unpaid dividends payable
pursuant to Section 4 or 5 will be paid in cash.

         (c) As used herein, the "Closing Price" for each day for any security
shall be the last reported sales price regular way or, in case no sale takes
place on such day, the average of the closing bid and asked prices regular way
on such day, in either case as reported on the principal national securities
exchange on which such security is listed or quoted (including, for this
purpose, the Nasdaq Stock Market), or, if not so listed or quoted, the average
of the high bid and low asked prices on such day as recorded by the Nasdaq Stock
Market, or, if the Nasdaq Stock Market shall not have reported any bid and asked
prices for such security on such day, the average of the bid and asked prices
for such day as furnished by any New York Stock Exchange member firm selected
from time to time by the Corporation for such purpose, or, if no such bid and
asked prices can be obtained from any such firm, the fair market value of such
security on such day as determined in good faith by the Board of Directors. Such
determination by the Board of Directors shall be conclusive.

         (d) No dividends or other distributions, other than dividends payable
solely in shares of Junior Stock, shall be paid or set apart for payment on, and
no purchase, redemption or other acquisition shall be made by the Corporation
of, any shares of Junior Stock unless and until all accrued and unpaid dividends
due on the Series B Convertible Preferred Stock (whether or not declared) shall
have been paid or declared and set apart for payment; provided, however, that
the conversion, exercise or exchange of a security for Junior Stock shall not be
deemed a purchase, redemption or acquisition of the security so converted or
exercised for purposes of this Section 3(d).

         (e) If at any time any dividend on any Senior Stock shall be in
default, in whole or in part, no dividend shall be paid or declared and set
apart for payment on the Series B Convertible Preferred Stock unless and until
all accrued and unpaid dividends with respect to the Senior Stock shall have
been paid or declared and set apart for payment, without interest.

         (f) No full dividends shall be paid or declared and set apart for
payment on any Parity Stock for any period unless all accrued but unpaid
dividends (whether or not declared) have been, or contemporaneously are, paid or
declared and set apart for such payment on the Series B Convertible Preferred
Stock. No full dividends shall be paid or declared and set apart for payment on
the Series B Convertible Preferred Stock for any period unless all accrued but
unpaid dividends (whether or not declared) have been, or contemporaneously are,
paid or declared and set apart for payment on the Parity Stock for all dividend
periods terminating on or prior to the date of payment of such full dividends.
When dividends are not paid in full upon the Series B Convertible Preferred
Stock and the Parity Stock, all dividends paid or declared and set apart for
payment upon shares of Series B

<PAGE>

Convertible Preferred Stock and the Parity Stock shall be paid or declared and
set apart for payment pro rata, so that the amount of dividends paid or declared
and set apart for payment per share on the Series B Convertible Preferred Stock
and the Parity Stock shall in all cases bear to each other the same ratio that
accrued and unpaid dividends per share on the shares of Series B Convertible
Preferred Stock and the Parity Stock bear to each other. Any reference to
"distribution" contained in this Section 3 shall not be deemed to include any
distribution made in connection with any liquidation, dissolution or winding up
of the Corporation, whether voluntary or involuntary.

         Section 4. Liquidation Preference. In the event of a liquidation,
dissolution or winding up of the Corporation, whether voluntary or involuntary,
the holders of Series B Convertible Preferred Stock shall be entitled to receive
out of the assets of the Corporation, whether such assets constitute stated
capital or surplus of any nature, a sum in cash equal to $_____ per share (the
"Liquidation Preference"), together with an amount equal to the dividends
accrued and unpaid thereon (whether or not declared) to the date of final
distribution to such holders, without interest, and no more, before any payment
shall be made or any assets distributed to the holders of any Junior Stock;
provided, however, that such rights shall accrue to the holders of Series B
Convertible Preferred Stock only if the Corporation's payments with respect to
the liquidation preference of the holders of Senior Stock are fully met. After
the liquidation preferences of the Senior Stock are fully met, the entire assets
of the Corporation available for distribution shall be distributed ratably among
the holders of the Series B Convertible Preferred Stock and any Parity Stock in
proportion to the respective preferential amounts to which each is entitled (but
only to the extent of such preferential amounts). After payment in full of the
accrued and unpaid dividends and the Liquidation Preference of the shares of the
Series B Convertible Preferred Stock as provided in this Section 4, the holders
of such shares shall not be entitled to any further participation in any
distribution of assets by the Corporation. Neither a consolidation or merger of
the Corporation with another corporation nor a sale or transfer of all or part
of the Corporation's assets for cash, securities or other property will be
considered a liquidation, dissolution or winding up of the Corporation.

         Section 5. Optional Redemption.

         (a) If at any time after __________, 2000 (the "Issue Date"), the
Closing Price of the Series B Convertible Preferred Stock shall be $______ or
more per share for any 21 consecutive trading days, the Corporation, at its
option, may at any time (until the date that is five days after the last trading
day used in determining the Closing Price for such 21 consecutive trading day
period) give notice in accordance with Section 5(c) that it will redeem all, but
not less than all, of the Series B Convertible Preferred Stock (an "Optional
Price-Based Redemption") at a sum in cash equal to

<PAGE>

the Liquidation Preference per share, together with an amount equal to the
dividends accrued and unpaid thereon (whether or not declared), pro rata to the
date fixed for redemption.

         (b) At any time after the date that is 180 days after the Issue Date,
the Corporation, at its option, may redeem (an "Optional Time-Based Redemption")
all, but not less than all, of the Series B Convertible Preferred Stock on any
date set by the Board of Directors, at the price per share set forth below (the
"Principal Price"), plus, in each case, an amount in cash per share equal to the
dividends accrued and unpaid thereon (whether or not declared), pro rata to the
date fixed for redemption. The Principal Price for an Optional Time-Based
Redemption shall be as follows:

If the date of the Optional Time-Based
Redemption is:                                 The Principal Price Shall Be:

more than 180 days after the Issue
Date and less than 12 months after
the Issue Date                                ___% of the Liquidation Preference

12 months or more after the Issue
Date and less than 24 months after
the Issue Date                                ___% of the Liquidation Preference

24 months or more after the Issue
Date and less than 36 months after
the Issue Date                                ___% of the Liquidation Preference

36 months or more after the Issue             ___% of the Liquidation Preference
Date and at any time thereafter

         (c) Not more than 60 nor less than 15 days prior to any redemption
date, notice by first class mail, postage prepaid, shall be given to the holders
of record of the Series B Convertible Preferred Stock, addressed to such
stockholders at their last addresses as shown on the books of the Corporation.
Each such notice of redemption shall specify the date fixed for redemption, the
redemption price, the place or places of payment, the then effective Conversion
Rate (as hereinafter defined), that the right of holders of shares of Series B
Convertible Preferred Stock being redeemed to exercise their conversion right
shall terminate as to such shares at the close of business on the day that
immediately precedes the date that is fixed for redemption (provided that no
default by the Corporation in the payment of the applicable redemption price
shall have occurred and be continuing), that payment will be made upon
presentation and surrender of the shares of Series B Convertible Preferred
Stock, that accrued but unpaid dividends to the date fixed for redemption
(whether or not declared) will be paid on the date fixed for redemption, and
that on

<PAGE>

and after the redemption date, dividends will cease to accrue on such shares.

         (d) Any notice which is mailed as herein provided shall be conclusively
presumed to have been duly given, whether or not the holder of the Series B
Convertible Preferred Stock receives such notice; and failure to give such
notice by mail, or any defect in such notice, to the holders of any shares
designated for redemption shall not affect the validity of the proceedings for
the redemption of any other shares of Series B Convertible Preferred Stock. On
or after the date fixed for redemption as stated in such notice, each holder of
the shares shall surrender the certificate (or certificates) evidencing such
shares to the Corporation at the place designated in such notice and shall
thereupon be entitled to receive payment of the applicable redemption price. If,
on the date fixed for redemption, funds necessary for the redemption shall be
available therefor and shall have been irrevocably deposited or set aside, then,
notwithstanding that the certificates evidencing any shares so called for
redemption shall not have been surrendered, the dividends with respect to the
shares so called shall cease to accrue after the date fixed for redemption, the
shares shall no longer be deemed outstanding, the holders thereof shall cease to
be stockholders, and all rights whatsoever with respect to the shares so called
for redemption (except the right of the holders to receive the applicable
redemption price, without interest, upon surrender of their certificates
therefor) shall terminate. Any monies deposited by the Corporation pursuant to
the foregoing provision and unclaimed at the end of one year from the date fixed
for redemption shall, to the extent permitted by law, be returned to the
Corporation, after which the holders of shares of Series B Convertible Preferred
Stock so called for redemption shall look only to the Corporation for the
payment thereof.

         Section 6. No Sinking Fund.

         The shares of Series B Convertible Preferred Stock shall not be subject
to the operation of a purchase, retirement or sinking fund.

         Section 7. Conversion.

         (a) At any time after the Issue Date but not later than the close of
business on the day preceding the date fixed for the redemption of the Series B
Convertible Preferred Stock in any notice of redemption given pursuant to the
provisions of Section 5 hereof if there is no default in payment of the
applicable redemption price, the holders of the Series B Convertible Preferred
Stock may, upon surrender of the certificates therefor, convert any or all of
their shares of Series B Convertible Preferred Stock into fully paid and
nonassessable shares of Common Stock and such other securities and property as
hereinafter provided. Each share of Series B Convertible Preferred Stock shall
be convertible at the office of any transfer agent for the Series B Convertible
Preferred Stock, and at such other office or offices, if any, as the Board of
Directors may designate, into that number of fully paid and nonassessable shares
of Common Stock (calculated as to each conversion

<PAGE>

to the nearest 1/100th of a share) as shall be equal to the Conversion Rate,
determined as hereinafter provided, in effect at the time of conversion. Shares
of Series B Convertible Preferred Stock may initially be converted into full
shares of Common Stock at the rate of _______ shares of Common Stock for each
share of Series B Convertible Preferred Stock subject to adjustment as
hereinafter provided (the "Conversion Rate"). Notwithstanding anything in this
Section 7 to the contrary, no change in the Conversion Rate shall actually be
made until the cumulative effect of the adjustments called for by this Section 7
since the date of the last change in the Conversion Rate would change the
Conversion Rate by more than 1%. However, once the cumulative effect would
result in such a change, the Conversion Rate shall actually be changed to
reflect all adjustments called for by this Section 7 and not previously made.

         (b) The right of the holders of Series B Convertible Preferred Stock to
convert their shares shall be exercised by surrendering for such purpose to the
Corporation or its agent, as provided above, certificates representing shares to
be converted, duly endorsed in blank or accompanied by proper instruments of
transfer and a notice of conversion. The Corporation shall not, however, be
required to pay any tax which may be payable in respect of any transfer involved
in the issue and delivery upon conversion of shares of Common Stock or other
securities or property in a name other than that of the holder of the shares of
the Series B Convertible Preferred Stock being converted, and the Corporation
shall not be required to issue or deliver any such shares or other securities or
property unless and until the person or persons requesting the issuance thereof
shall have paid to the Corporation the amount of any such tax or shall have
established to the satisfaction of the Corporation that such tax has been paid.

         (c) The Corporation (and any successor corporation) shall take all
action necessary so that a number of shares of the authorized but unissued
Common Stock (or common stock in the case of any successor corporation)
sufficient to provide for the conversion of the Series B Convertible Preferred
Stock outstanding upon the basis hereinbefore provided are at all times reserved
by the Corporation (or any successor corporation), free from preemptive rights,
for such conversion, subject to the provisions of Section 7(d). If the
Corporation shall issue any securities or make any change in its capital
structure which would change the number of shares of Common Stock into which
each share of the Series B Convertible Preferred Stock shall be convertible as
herein provided, the Corporation shall at the same time also make proper
provision so that thereafter there shall be a sufficient number of shares of
Common Stock authorized and reserved, free from preemptive rights, for
conversion of the outstanding Series B Convertible Preferred Stock on the new
basis.

         (d) In case of any consolidation or merger of the Corporation with any
other corporation or in case of any sale or transfer of all or substantially all
of the assets of the Corporation, or in the case of any share exchange, in each
case

<PAGE>

pursuant to which all of the outstanding shares of Common Stock are converted
into other securities, cash or other property, the Corporation shall make
appropriate provision or cause appropriate provision to be made so that each
holder of shares of Series B Convertible Preferred Stock then outstanding shall
have the right thereafter (in lieu of the right to convert into Common Stock,
which right shall cease) to convert such shares of Series B Convertible
Preferred Stock into the kind and amount of securities, cash or other property
receivable upon such consolidation, merger, sale, transfer or share exchange by
a holder of the number of shares of Common Stock into which such shares of
Series B Convertible Preferred Stock could have been converted immediately prior
to the effective date of such consolidation, merger, sale, transfer or share
exchange. If, in connection with any such consolidation, merger, sale, transfer
or share exchange, each holder of shares of Common Stock is entitled to elect to
receive either securities, cash or other property upon completion of such
transaction, the Corporation shall provide or cause to be provided to each
holder of Series B Convertible Preferred Stock the right to elect the
securities, cash (other than by the exercise of appraisal rights) or other
property into which the Series B Convertible Preferred Stock held by such holder
shall be convertible after completion of any such transaction on the same terms
and subject to the same conditions applicable to holders of the Common Stock
(including, without limitation, notice of the right to elect, limitations on the
period in which such election shall be made and the effect of failing to
exercise the election). The Corporation shall not effect any such transaction
unless the provisions of this Section 7(d) have been complied with. The above
provisions shall similarly apply to successive consolidations, mergers, sales,
transfers or share exchanges.

         (e) Upon the surrender of certificates representing shares of Series B
Convertible Preferred Stock, the person converting shall be deemed to be the
holder of record of the Common Stock issuable upon such conversion, and all
rights with respect to the shares surrendered shall forthwith terminate except
the right to receive the Common Stock or other securities, cash or other
property as herein provided.

         (f) No fractional shares of Common Stock shall be issued upon
conversion of Series B Convertible Preferred Stock but, in lieu of any fraction
of a share of Common Stock which would otherwise be issuable in respect of the
aggregate number of such shares surrendered for conversion at one time by the
same holder, the Corporation shall pay in cash an amount equal to the product of
(i) the Closing Price of a share of Common Stock on the last trading day before
the conversion date and (ii) such fraction of a share.

         (g) The Conversion Rate shall be adjusted from time to time under
certain circumstances, subject to the provisions of the last two sentences of
Section 7(a), as follows:

<PAGE>

                  (i) In case the Corporation shall (A) pay a dividend or make a
         distribution on its Common Stock in shares of its capital stock, (B)
         subdivide its outstanding Common Stock into a greater number of shares,
         (C) combine the shares of its outstanding Common Stock into a smaller
         number of shares, or (D) issue by reclassification of its Common Stock
         any shares of its capital stock, then in each such case the Conversion
         Rate in effect immediately prior thereto shall be proportionately
         adjusted so that the holder of any Series B Convertible Preferred Stock
         thereafter surrendered for conversion shall be entitled to receive, to
         the extent permitted by applicable law, the number and kind of shares
         of capital stock of the Corporation which it would have owned or have
         been entitled to receive after the happening of such event had such
         Series B Convertible Preferred Stock been converted immediately prior
         to the record date for such event (or if no record date has been
         established in connection with such event, the effective date for such
         action). An adjustment pursuant to this Section 7(g)(i) shall become
         effective immediately after the record date in the case of a stock
         dividend or distribution and shall become effective immediately after
         the effective date in the case of a subdivision, combination, or
         reclassification.

                  (ii) In case the Corporation shall issue rights or warrants to
         all holders of the Common Stock entitling such holders to subscribe for
         or purchase Common Stock on the record date referred to below at a
         price per share less than the average daily Closing Prices of the
         Common Stock on the 30 consecutive trading days commencing 45 business
         days before such record date (the "Current Market Price"), then in each
         such case the Conversion Rate in effect on such record date shall be
         adjusted in accordance with the formula

            c1 = C x     O + N
                         --------
                         O + N x P
                             -----
                               M

where

      c1 =  the adjusted Conversion Rate.

      C  =  the current Conversion Rate (immediately preceding the issuance of
            such rights or warrrants).

      O  =  the number of shares of Common Stock outstanding on the record
            date.

      N  =  the number of additional shares of Common Stock issuable pursuant
            to

<PAGE>

            the exercise of such rights or warrants.

      P  =  the exercise price per share of such rights or warrants.

      M  =  the Current Market Price per share of Common Stock on such record
            date.

Such adjustment shall become effective immediately after the record date for the
determination of stockholders entitled to receive such rights or warrants. If
any or all of such rights or warrants are not so issued or expire or terminate
before being exercised, the Conversion Rate then in effect shall be readjusted
appropriately.

                  (iii) In case the Corporation shall, by dividend or otherwise,
         distribute to all holders of its Junior Stock or Parity Stock evidences
         of its indebtedness or assets (including cash or securities, but
         excluding any warrants or subscription rights referred to in Section
         7(g)(ii) above, any ordinary dividend paid in cash out of the retained
         earnings of the Corporation and any dividend or distribution referred
         to in Section 7(g)(i) above), then in each such case the Conversion
         Rate then in affect shall be adjusted in accordance with the formula

            c1 = C x     M
                        ---
                        M-F

where

      c1 =  the adjusted Conversion Rate.

      C  =  the current Conversion Rate (immediately preceding such
            distribution).

      M  =  the Current Market Price per share of Common Stock with respect to
            the record date mentioned below.

      F  =  the aggregate amount of such cash dividend and/or the fair market
            value on such record date of the assets or securities to be
            distributed, divided by the number of shares of Common Stock
            outstanding on the record date. In the case of securities, the fair
            market value shall be the average of the daily Closing Price for the
            30 trading days preceding such record date (or such fewer number of
            days for which there shall be a recognized trading market);
            provided, however, that if there shall not be any recognized trading
            market for such securities until after such record date, the fair
            market value shall be the average of the daily Closing Price for the
            10 trading days following such record date. In all other cases, the
            Board of Directors shall determine such

<PAGE>

            fair market value, which determination shall be conclusive.

Such adjustment shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution.

                  (iv) All calculations hereunder shall be made to the nearest
         cent or to the nearest 1/100 of a share, as the case may be.

                  (v) If at any time as a result of an adjustment made pursuant
         to Section 7(g)(i), the holder of any Series B Convertible Preferred
         Stock thereafter surrendered for conversion shall become entitled to
         receive securities, cash, or assets other than Common Stock, the number
         or amount of such securities or property so receivable upon conversion
         shall be subject to adjustment from time to time in a manner and on
         terms as nearly equivalent as practicable to the provisions with
         respect to the Common Stock contained in Section 7(g)(i) to (iv),
         inclusive, above.

         (h) Except as otherwise provided above in this Section 7, no adjustment
in the Conversion Rate shall be made in respect of any conversion for share
distributions or dividends theretofore declared and paid or payable on the
Common Stock.

         (i) Whenever the Conversion Rate is adjusted as herein provided, the
Corporation shall send to each transfer agent for the Series B Convertible
Preferred Stock and the Common Stock, and to the principal securities exchange,
if any, on which the Series B Convertible Preferred Stock and the Common Stock
is traded, or the Nasdaq Stock Market if the Series B Convertible Preferred
Stock or Common Stock is admitted for quotation thereon, a statement signed by
the Chairman of the Board, the President, or any Vice President of the
Corporation and by its Treasurer or its Secretary or Assistant Secretary stating
the adjusted Conversion Rate determined as provided in this Section 7, and any
adjustment so evidenced, given in good faith, shall be binding upon all
stockholders and upon the Corporation. Whenever the Conversion Rate is adjusted,
the Corporation will give notice by mail to the holders of record of Series B
Convertible Preferred Stock, which notice shall be made within 45 days after the
effective date of such adjustment and shall state the adjustment and the
Conversion Rate. Notwithstanding the foregoing notice provisions, failure by the
Corporation to give such notice or a defect in such notice shall not affect the
binding nature of such corporate action of the Corporation.

         (j) Whenever the Corporation shall propose to take any of the actions
specified in Section 7(d) or in Section 7(g)(i), (ii) or (iii) which would
result in any adjustment in the Conversion Rate under this Section 7, the
Corporation shall use its best efforts to cause a notice to be mailed at least
20 days prior to the date on which the books of the Corporation will close or on
which a record will be taken for such action, to the holders of record of the
outstanding Series B Convertible

<PAGE>

Preferred Stock on the date of such notice. Such notice shall specify the action
proposed to be taken by the Corporation and the date as of which holders of
record of the Common Stock shall participate in any such actions or be entitled
to exchange their Common Stock for securities or other property, as the case may
be. Failure by the Corporation to mail the notice or any defect in such notice
shall not affect the validity of the transaction.

         (k) Notwithstanding any other provision of this Section 7, no
adjustment in the Conversion Rate need be made (i) for a transaction referred to
in Section 7(g)(i), (ii) or (iii) if holders of Series B Convertible Preferred
Stock are to participate in the transaction or distribution on a basis and with
notice that the Board of Directors reasonably determines such transaction to be
fair to the holders of the Series B Convertible Preferred Stock and appropriate
in light of the basis on which holders of Common Stock or, in the case of a
transaction referred to in Section 7(g)(iii), holders of Junior Stock
participate in the transaction; (ii) for sales of Common Stock pursuant to a
plan for reinvestment of dividends and interest, provided that the purchase
price in any such sale is at least equal to 90% of the fair market value of the
Common Stock at the time of such purchase, or pursuant to any plan adopted by
the Corporation for the benefit of its employees, directors or consultants;
(iii) for a change in par value of the Common Stock not involving a subdivision
or combination described in Section 7(g)(i)(B) or 7(g)(i)(C); or (iv) after the
Series B Convertible Preferred Stock becomes convertible solely into cash by
reason of an adjustment pursuant to Section 7(d) hereof.

         Section 8. Voting Rights.

         (a) The holders of Series B Convertible Preferred Stock will not have
any voting rights except as set forth in this Section 8 or as otherwise from
time to time required by law.

         (b) The affirmative vote or consent of the holders of at least a
majority of the outstanding shares of the Series B Convertible Preferred Stock,
voting separately as a class, will be required for (i) the issuance of any
Senior Stock or Parity Stock or (ii) any amendment, alteration or repeal of this
Certificate of Designation if such amendment, alteration or repeal materially
and adversely affects the powers, preferences or special rights of the Series B
Convertible Preferred Stock. The creation, authorization or issuance of any
shares of any Junior Stock or the increase or decrease in the amount of
authorized capital stock of any class, including preferred stock, shall not
require the consent of holders of the Series B Convertible Preferred Stock and
shall not be deemed to affect adversely the rights, preferences, privileges or
voting rights of shares of Series B Convertible Preferred Stock. Such right of
the holders of Series B Convertible Preferred Stock to vote as hereinabove
provided may be exercised at any annual meeting or at any special meeting called
for such purpose as hereinafter provided or at any adjournment thereof.

<PAGE>

         (c) If dividends on the Series B Convertible Preferred Stock are in
arrears and unpaid for six or more dividend periods (whether or not consecutive)
(a "Dividend Default"), then the number of directors constituting the Board of
Directors of the Corporation will be increased by two and the holders of the
then outstanding shares of Series B Convertible Preferred Stock (together with
the holders of Parity Stock upon which like rights have been conferred and are
exercisable), voting separately and as a class, shall have the right and power
to elect such two additional directors. The occurrence of a Dividend Default is
a "Voting Rights Triggering Event." A Voting Rights Triggering Event shall not
be deemed to have occurred if at the time of such event there are less than
25,000 shares of Series B Convertible Preferred Stock then outstanding.

         (d) The voting rights set forth in Section 8(c) will continue until
such time as (x) in the case of a default in the payment of dividends, all
dividends in arrears on the Series B Convertible Preferred Stock are paid in
full or (y) there are fewer than 25,000 shares of Series B Convertible Preferred
Stock outstanding, at which time the term of any directors elected pursuant to
the provisions of Section 8(c) shall terminate and the number of directors
constituting the Board of Directors shall be decreased by two (until the
occurrence of any subsequent Voting Rights Triggering Event). At any time after
voting power to elect directors shall have become vested and be continuing in
the holders of Series B Convertible Preferred Stock pursuant to Section 8(c), or
if vacancies shall exist in the offices of directors elected by such holders, a
proper officer of the Corporation may, and upon the written request of the
holders of record of at least 25% of the shares of Series B Convertible
Preferred Stock then outstanding addressed to the Secretary of the Corporation
shall, call a special meeting of the holders of Series B Convertible Preferred
Stock; provided, however, that no such special meeting shall be called if the
next annual meeting of stockholders of the Corporation is to be held within 60
days after the voting power to elect directors shall have become vested, in
which case such meeting shall be deemed to have been called for such next annual
meeting. If such meeting shall not be called by a proper officer of the
Corporation within 20 days after personal service to the Secretary of the
Corporation at its principal executive offices, then the holders of record of at
least 25% of the outstanding shares of Series B Convertible Preferred Stock may
designate in writing one of their members to call such meeting at the expense of
the Corporation, and such meeting may be called by the person so designated upon
the notice required for the annual meetings of stockholders of the Corporation
and shall be held at the place for holding the annual meetings of stockholders.
Any holder of Series B Convertible Preferred Stock so designated shall have, and
the Corporation shall provide, access to the lists of holders of Series B
Convertible Preferred Stock to be called pursuant to the provisions hereof. If
no special meeting of the holders of Series B Convertible Preferred Stock is
called as provided in this Section 8(d), then such meeting shall be deemed to
have been called for the next annual meeting of stockholders of the Corporation
or special meeting of the holders of any other

<PAGE>

capital stock of the Corporation.

         (e) At any meeting held for the purposes of electing directors at which
the holders of Series B Convertible Preferred Stock (together with the holders
of Parity Stock upon which like rights have been conferred and are exercisable)
shall have the right, voting together as a separate class, to elect directors as
aforesaid, the presence in person or by proxy of the holders of at least a
majority in voting power of the outstanding shares of Series B Convertible
Preferred Stock (and such Parity stock) shall be required to constitute a quorum
thereof.

         (f) Any vacancy occurring in the office of a director elected by the
holders of Series B Convertible Preferred Stock (and such Parity Stock) may be
filled by the remaining director elected by the holders of Series B Convertible
Preferred Stock (and such Parity Stock) unless and until such vacancy shall be
filled by the holders of Series B Convertible Preferred Stock (and such Parity
Stock).

         (g) In any case in which the holders of Series B Convertible Preferred
Stock shall be entitled to vote pursuant to this Section 8 or pursuant to
Delaware law, each holder of Series B Convertible Preferred Stock entitled to
vote with respect to such matters shall be entitled to one vote for each share
of Series B Convertible Preferred Stock held.

         Section 9. Outstanding Shares. All shares of Series B Convertible
Preferred Stock shall be deemed outstanding except: (i) from the date fixed for
redemption pursuant to Section 5 hereof, all shares of Series B Convertible
Preferred Stock which have been so called for redemption under Section 5, if
funds necessary for such redemption of such shares are available; (ii) from the
date of surrender of certificates representing shares of Series B Convertible
Preferred Stock for conversion into Common Stock, all shares of Series B
Convertible Preferred Stock converted into Common Stock; and (iii) from the date
of registration of transfer, all shares of Series B Convertible Preferred Stock
held of record by the Corporation or any subsidiary of the Corporation.

         IN WITNESS WHEREOF, Frontline Communications Corporation has caused its
corporate seal to be hereunto affixed and this certificate to be signed by
Stephen J. Cole-Hatchard, its Chief Executive Officer this ____ day of , 2000.

                              FRONTLINE COMMUNICATIONS CORPORATION

                              By
                                --------------------------------------------
                              Stephen J. Cole-Hatchard
                              Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]